The Impact of a Genomic Assay on Urologist Treatment Preference in Active Surveillance-Eligible Men
Northwestern
Thursday, March 9 at 12 PM Central Dr. Adam Murphy will summarize the results of a randomized controlled trial assessing the impact of a Genomic Assay on urologists and patients treatment preferences for favorable risk. prostate cancer. Guest: Adam B. Murphy, MD, MBA, MSCI Assitant Professor of Urology & Preventive Medicine Northwestern University Feinberg School